Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP943 monotherapy in advanced CD123+ hematologic malignancies
NCT06034275Phase 1Recruiting
- Sponsor
- Vincerx
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VIP943 in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Vincerx. Primary endpoint: Incidence of Dose Limiting Toxicity. Started Sep 2023; status: recruiting.
02
Drugs
VIP943
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06034275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034275.